INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
05/20/2025
Back to search
Official data from USPTO
MABFC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
05/21/2025
Trademark type
Combined
Nice classes
5, 42
Filing date
12/14/2016
Registration date
03/06/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/20/2024
Last transaction
05/21/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
FR
Examiner
POWERS, ALEXANDER
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the Greek letter delta to the left of the stylized term "MABFC", with the letters "M" and "F" capitalized and the remainder in lower case letters.
Holders and representatives
Holders
L. B. (pessoa física)
Representatives
Monte L. Falcoff/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products and preparations for the treatment of cancerautoimmune disordersinflammatory disordersviral and bacterial infectionsblood diseases; medicines for cancerautoimmune disordersinflammatory disordersviral and bacterial infectionsblood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteinsbuffersreagents for use in disease testing
Class 42
Scientific and technological servicesscientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical productspharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancerautoimmune disordersinflammatory disordersviral and bacterial infectionsblood diseases; research and development in the field of the prevention and the treatment of cancerautoimmune disordersinflammatory disordersviral and bacterial infectionsblood diseases; cellular and molecular biological research; design and development of medical productspharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; testinginspection or research of pharmaceuticals; medical and scientific researchconducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; platform technologyprotein expression platform for research and development of pharmaceuticals; platform technologyprotein expression platform for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; laboratory services in the field of monoclonal antibodies
Publications
History of USPTO decisions and trademark events.
33 publications found
C71T
CANCELLED SECTION 71
09/20/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/04/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/06/2023
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/26/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/09/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
04/03/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/05/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/17/2018
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
06/08/2018
XXCR
GENERIC MADRID TRANSACTION CREATED
06/08/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
03/06/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/19/2017
PUBO
PUBLISHED FOR OPPOSITION
12/19/2017
GPNX
NOTIFICATION PROCESSED BY IB
12/15/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/29/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/29/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/29/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/15/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/14/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/14/2017
ALIE
ASSIGNED TO LIE
11/03/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/24/2017
RFNT
REFUSAL PROCESSED BY IB
06/03/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/18/2017
RFRR
REFUSAL PROCESSED BY MPU
05/18/2017
MAFR
APPLICATION FILING RECEIPT MAILED
05/12/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/11/2017
CNRT
NON-FINAL ACTION WRITTEN
05/10/2017
DOCK
ASSIGNED TO EXAMINER
05/08/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/08/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/04/2017
Continuous trademark protection
Get notified about every new filing that threatens MABFC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.